e15647Background: Hypermutation, which is a molecular subtype with high tumor mutation burden (TMB), has been recognized as a biomarker of anti-PD-1 therapy in many cancers. Hypermutation can be de... Click to show full abstract
e15647Background: Hypermutation, which is a molecular subtype with high tumor mutation burden (TMB), has been recognized as a biomarker of anti-PD-1 therapy in many cancers. Hypermutation can be de...
               
Click one of the above tabs to view related content.